Jul1123
CTO only spent approx. $1 mill /quarter on exploration costs.
That doesn't seem particularly excessive to me.
I'm sure exploration costs would be allocated correctly, according to ASIC rules, as the risks of masking costs would be too great for directors and CFO's to contemplate.
Also, to put it in perspective, $1 mill is about 800 oz... it wont mean much if CTO is producing at 15,000 oz/quarter, even if it does get wrongly allocated later on by an honest mistake say or the CFO has a brain fade.
Bottom line..
There's a standard way to calculate cash costs, that needs to be adhered to, it's not left to chance or interpretation.
In all instances for CTO and other ASX miners ..
Any costs that relate to the stope development for instance would fall under operating cash costs.
Any costs that relate to the Decline development would obviously be outside the operating cash costs... the Decline is seen as a capital item - an asset that can be amortised over a number of years.
No interpretation or masking would be tolerated.
- Forums
- ASX - By Stock
- CTO
- latest selling
latest selling, page-9
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CTO (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.4¢ | $4.433K | 1.108M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 11127183 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 13493272 | 22 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 11127183 | 0.003 |
8 | 10395025 | 0.002 |
9 | 14702988 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 13493272 | 22 |
0.006 | 5195133 | 8 |
0.007 | 2675523 | 4 |
0.008 | 1850000 | 4 |
0.009 | 2570800 | 5 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
CTO (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online